



Exhibitor & Sponsorship Prospectus

Mayo Clinic Urology Review 2027
Ivins, Utah
February 18, 2027 to February 21, 2027

Welcome

On behalf of the course directors **Aqsa Khan, M.D.**, and **Mark Tyson II, M.D., M.P.H.** and Mayo Clinic School of Continuous Professional Development, we are pleased to announce the upcoming **Mayo Clinic Urology Review 2027** course being held at the Black Desert Resort in Ivins, Utah.

This four-day CME course fits with urology conferences rotated by Mayo Clinic sites - Rochester (even years) and Arizona/Florida (odd years). The course reviews the diagnosis and management of urologic conditions, focusing on recent medical, surgical, and technological advances, and draws on the world-class expertise of Mayo Clinic urologists across all three sites.

Please visit the course website at ce.mayo.edu/urology2027 for additional details on the course. The Mayo Clinic Urology Review 2027 will be held at the Black Desert Resort. Guest rooms have been reserved at a discounted rate over the course dates. Room reservations must be made before January 25, 2027, or before the room block fills, whichever occurs first.

Black Desert Resort

1500 E Black Desert Dr
Ivins, UT 84738
United States

If you are interested in participating in this course, please complete the electronic Letter of Agreement Form. If you have not already done so, please [create an account](#) prior to signing our letter of agreement.

Mayo Clinic recognizes these types of educational programs would not be possible without your support. We have a variety of sponsorship opportunities for you to consider. If you do not see what you are looking for, contact us and we will be happy to discuss additional advertising opportunities.

We appreciate your consideration of this opportunity and hope to see you in February in Utah!

Sincerely,

Morgan Gish / Education Administration Coordinator Gish.Morgan@mayo.edu

Brady Watson / CME Specialist Watson.Brady@mayo.edu

Mayo Clinic Urology Review 2027

Overview:

This course offers a quality selection of marketing and advertising opportunities. These are designed to help companies further engage, network and connect with attendees during the annual conference. Mayo Clinic staff can help maximize exposure through additional advertising opportunities.

Why Sponsor:

Technical and educational exhibits provide a professional and educational environment in which physicians can receive demonstrations, view products and services and discuss the clinical and surgical uses of these products and services, including how they may improve the quality of care and the management of the medical/surgical practice. Additionally, the exhibits enhance the educational content of the meeting, helping to provide quality continuing medical education.

Benefits of Sponsorship:

- Interact face-to-face with numerous medical professionals
 - Build visibility for your company in a competitive marketplace
 - Expand your customer base and strengthen existing customer relationships
 - Introduce new products and services
 - Additional advertisement opportunities to expand reach and further socialize with attendees
- Sponsorships opportunities

Sponsorship & Exhibit Opportunities

Product Theatre - \$15,000.00 (Limit 3)

Showcase your product offerings to attendees with a product theatre.

- 45-minute breakfast session with complimentary meeting room space. Food and beverage will be provided by Mayo Clinic. Attendee list after the event, networking opportunities, and acknowledgment and recognition at the conference
- Sponsor is responsible for providing speaker(s), program invitations and advertisements for the product theatre.
- Sponsor is logistically and financially responsible for any/all audiovisual needs for the product theatre.

Signage at Breakfast - \$7,500.00 (Limit 4)

Help attendees stay connected with their office and home while away at the conference. Sponsor wireless internet access in the meeting space for the course attendees.

- Supporter will be recognized throughout the meeting in signage and electronic communications.
- Company name will be displayed outside the meeting space.

Attendee Bags - \$5,000.00 (Exclusive)

Prominently display your company name on attendee bags. Sponsor is responsible for sourcing the bags and providing to the CME staff to distribute to attendees once onsite at the course.

- Supporter will be recognized throughout the meeting in signage and electronic communications.
- Company name will be displayed outside the meeting space.

Exhibit Only - \$3,500.00 (Limit 25)

- One 6-foot exhibit tables
- Recognition in conference syllabus, signage, break slides & announcement from podium
- Attendee list (Opt-in only – name, city, and state)
- Access to networking opportunities throughout the course

Click here to secure your Exhibit/Sponsorship

A signed letter of agreement is required to secure your Exhibit/Sponsorship. This is a competitive course. Please consider signing our agreement early to secure Exhibit/Sponsorship.

Set-up: Wednesday, February 17th – Time 2:00pm – 4:00pm

Exhibit Hours – Wednesday, February 18th at 6:00 am to Friday, February 21st at 12:00 pm

Tear Down: Sunday, February 21st – at conclusion of course

Payment Options:

PREFERRED Payment: Credit card

To pay by credit card, please click [here](#)

By Check: Make checks payable to:

Mayo Clinic - MCSCPD

200 First St SW

Plummer 2-60, Attn: Morgan Gish

Rochester, MN 55905

Reference: Urology Review 5327R01808 on check

Mayo Clinic Tax ID: 41-6011702



Mayo Clinic Urology Review 2027
February 18 – 21, 2027
Black Desert Resort – Ivins, Utah

All Presentations in Mountain Standard Time (UTC - 7 Hours)

Thursday, February 18, 2027	
6:30 AM - 7:50 AM	Registration & Breakfast
7:50 AM - 8:00 AM	Introduction to Oncology: Bladder Cancer <i>Moderators: Mark Tyson II, M.D., M.P.H. / Timothy Lyon, M.D.</i>
8:00 AM - 8:20 AM	Overview of New Intravesical Therapies for NMIBC <i>Mark Tyson II, M.D., M.P.H.</i>
8:20 AM - 8:40 AM	Managing Side Effects of New Intravesical Therapies <i>Chris Ferguson, P.A.-C.</i>
8:40 AM - 9:00 AM	Creative Ways to Navigate the BCG Shortage <i>Timothy Lyon, M.D.</i>
9:00 AM - 9:20 AM	The Finer Points of the Guidelines for Bladder Cancer <i>Sam Chang, M.D. (Vanderbilt University Medical Center)</i>
9:20 AM - 9:40 AM	Updates in Perioperative Systemic Therapy for MIBC <i>Parminder Singh, M.D.</i>
9:40 AM - 10:00 AM	Bladder Preservation following CR after Neoadjuvant Therapy <i>Josh Niska, M.D.</i>
10:00 AM - 10:10 AM	Case Discussions in Bladder Cancer
10:10 AM - 10:40 AM	BREAK
10:40 AM - 10:50 AM	Introduction to Non-oncology: Endo/Stones/BPH <i>Moderators: Christopher Wolter, M.D. & Aqsa Khan, M.D.</i>
10:50 AM - 11:10 AM	When Urodynamics Actually Change Management <i>Mackenzie Gibbs, M.D.</i>
11:10 AM - 11:30 AM	Neuromodulation in 2027: SNM, PTNS, and What's New <i>Christopher Wolter, M.D.</i>
11:30 AM - 11:50 AM	OAB Management in Men: What to Do If the Outlet's Not the Problem <i>Meghan Cooper, D.O.</i>
11:50 AM - 12:10 PM	POP Surgery in the Elderly: Balancing Risk and Benefit <i>Aqsa Khan, M.D.</i>
12:10 PM - 12:30 PM	Sling Erosion and Complications: Recognition and Management <i>Steven Petrou, M.D.</i>
12:30 PM - 12:50 PM	Radiation-Induced Lower Urinary Tract Dysfunction: Tips and Tricks for Management <i>Katie Anderson, M.D.</i>
12:50 PM - 1:05 PM	Panel / Discussion
1:05 PM	ADJOURN



Mayo Clinic Urology Review 2027
February 18 – 21, 2027
Black Desert Resort – Ivins, Utah

All Presentations in Mountain Standard Time (UTC - 7 Hours)

Friday, February 19, 2027	
6:30 AM - 7:50 AM	Breakfast & Exhibits
7:50 AM - 8:00 AM	Introduction to Oncology: Prostate Cancer <i>Moderators: Jack Andrews, M.D. / Jacob Orme, M.D., Ph.D.</i>
8:00 AM - 8:20 AM	Introduction and What does the Urologist need to know about PSMA Imaging? <i>Jack Andrews, M.D.</i>
8:20 AM - 8:40 AM	Advancements in RT therapy for Localized Prostate Cancer. Trials and Data the Urologist Needs to Know <i>Brad Stish, M.D.</i>
8:40 AM - 9:00 AM	Focal Therapy, Current Recommendations and Future Directions <i>Dan Frendl, M.D., Ph.D.</i>
9:00 AM - 9:20 AM	Pushing the Limits of Active Surveillance <i>Paras Shah, M.D.</i>
9:20 AM - 9:40 AM	Novel Techniques for RARP, Are They Really Better? <i>Ram Pathak, M.D.</i>
9:40 AM - 10:00 AM	Tips and Tricks for the Difficult Prostatectomy <i>Igor Frank, M.D.</i>
10:00 AM - 10:20 AM	Management of BCR and Insights from the BRIO Trial <i>Vidit Sharma, M.D.</i>
10:20 AM - 10:30 AM	Panel / Discussion <i>Jack Andrews, M.D.</i>
10:30 AM - 11:00 AM	BREAK
11:00 AM - 11:10 AM	Introduction to Non-Oncology: Peds/GURS <i>Moderators: Bridget Findlay, M.D. / Boyd Viers, M.D.</i>
11:10 AM - 11:30 AM	Common Pediatric Emergencies for the Adult Urologist: Principles and Novel Advancements <i>Patricio Gargollo, M.D.</i>
11:30 AM - 11:50 AM	Hypospadias and Urethral Reconstruction: When to Refer <i>Candace Granberg, M.D.</i>
11:50 AM - 12:10 PM	Longitudinal Care of the Congenital Urology Patient: Key Considerations for Pediatric to Adult Transition <i>Bridget Findlay, M.D.</i>
12:10 PM - 12:30 PM	Transluminal Urethroplasty: New Frontier in Urethral Reconstruction <i>Nick Warner, M.D.</i>
12:30 PM - 12:50 PM	Surgical Management of Upper Tract Obstruction <i>Boyd Viers, M.D.</i>
12:50 PM - 1:20 PM	Post-Prostatectomy Incontinence: Surgical Decision-Making <i>Christopher Wolter, M.D.</i>
1:20 PM - 1:35 PM	Panel / Discussion
1:35 PM	ADJOURN



Mayo Clinic Urology Review 2027
February 18 – 21, 2027
Black Desert Resort – Ivins, Utah

All Presentations in Mountain Standard Time (UTC - 7 Hours)

Saturday, February 20, 2027	
6:30 AM - 7:50 AM	Breakfast & Exhibits
7:50 AM - 8:00 AM	Introduction to Oncology: Kidney / Testicular Cancer <i>Moderators: Scott Cheney, M.D. / David Thiel, M.D.</i>
8:00 AM - 8:20 AM	Minimally Invasive Renal Surgery - Managing Difficult Situations or a Complications Talk. <i>David Thiel, M.D.</i>
8:20 AM - 8:40 AM	Ablation - which modality and who? (Cryo vs RFA vs Histosonics vs Microwave) <i>Greg Frey, M.D.</i>
8:40 AM - 9:00 AM	Systemic Tx in RCC <i>Bradley Leibovich, M.D.</i>
9:00 AM - 9:20 AM	10 Things to know About RCC Imaging <i>Kelly Cox, D.O.</i>
9:20 AM - 9:40 AM	CTDna and Other Biomarkers in RCC (Including AI) - Ready for Primetime? <i>Yousef Zakharia, M.D.</i>
9:40 AM - 10:00 AM	SBRT for Small Renal Masses <i>Mohammadi, Homan, M.D.</i>
10:00 AM - 10:10 AM	Panel / Discussion
10:10 AM - 10:40 AM	BREAK
10:40 AM - 10:45 AM	Introduction to Endo/Stones/BPH <i>Moderators: Karen Stern, M.D. & Mitchell Humphreys, M.D.</i>
10:45 AM - 11:00 AM	Metabolic Urine Evaluation: Fundamentals of Interpretation – And do we still need it? <i>Peggy Pearle, M.D., Ph.D. (UT Southwestern Medical Center)</i>
11:00 AM - 11:20 AM	Debate: Asymptomatic 8 mm Renal Stone – What to do Ureteroscopy – Raymond Pak, M.D. Shockwave - Victoria Edmonds, M.D. Observation - Peggy Pearle, M.D., Ph.D. Moderator: Mitchell Humphreys, M.D.
11:20 AM – 11:35 AM	Updates in Stone Surgery – What's New? <i>Karen Stern, M.D.</i>
11:35 AM - 11:45 AM	Panel/Discussion/Questions
11:45 AM – 12:00 PM	Quality of life and BPH – What matters? <i>Kevin Wymer, M.D.</i>
12:00 PM - 12:15 PM	Medical Therapy for BPH – Is there still a role? <i>Dane Klett, M.D.</i>
12:15 PM - 12:30 PM	Matching the prostate to the procedure – Do MIST procedures have a place? <i>Scott Cheney, M.D.</i>
12:30 PM - 12:45 PM	Complications / Failures after BPH – Salvage Options <i>Bridget Findlay, M.D.</i>
12:45 PM - 1:05 PM	Panel / Discussion
1:05 PM	ADJOURN



Mayo Clinic Urology Review 2027
February 18 – 21, 2027
Black Desert Resort – Ivins, Utah

All Presentations in Mountain Standard Time (UTC - 7 Hours)

Sunday, February 21, 2027	
6:30 AM - 7:50 AM	Breakfast & Exhibits
7:50 AM - 8:00 AM	Introduction to Men's Health/ Infertility / Transplant <i>Moderators: Nahid Punjani, M.D., M.P.H. / Bryce Baird, M.D.</i>
8:00 AM - 8:20 AM	New and Novel Therapies for Erectile Dysfunction <i>Bryce Baird, M.D.</i>
8:20 AM - 8:40 AM	Testosterone Therapy: Evidence, Safety, and Monitoring <i>Tobias Kohler, M.D., M.P.H.</i>
8:40 AM - 9:00 AM	Male Infertility: What the General Urologist Should Do <i>Sevann Helo, M.D.</i>
9:00 AM - 9:20 AM	Practical Approach to Chronic Scrotal Pain <i>Kelli Gross, M.D. (University of Utah Health)</i>
9:20 AM - 9:40 AM	The Role of the Urologist in Renal Transplantation <i>George Chow, M.D.</i>
9:40 AM - 10:00 AM	Fertility Preservation in Oncology Patients <i>Nahid Punjani, M.D., M.P.H.</i>
10:00 AM - 10:10 AM	Panel / Discussion
10:10 AM - 10:40 AM	BREAK
10:40 AM - 10:50 AM	Introduction to Reflections & Future of Urology, Policy Session <i>Moderators: Dan Frenzl, M.D., Ph.D. / Abhinav Khanna, M.D.</i>
10:50 AM - 11:10 AM	Artificial Intelligence in Urology: Practical Applications Today <i>Abhinav Khanna, M.D.</i>
11:10 AM - 11:30 AM	The Future of Urology Practice: What Will Change by 2030 <i>Kevin Koo, M.D., M.P.H.</i>
11:30 AM - 11:50 AM	Perioperative Optimization in the GLP-1 Era <i>Anna Ward, M.D.</i>
11:50 AM - 12:10 PM	Medical Urology Practice: Pros and Cons <i>Vidal Despradel, M.D.</i>
12:10 PM - 12:30 PM	Building a Meaningful Career in Urology: Lessons from Over Time <i>Peggy Pearle, M.D., Ph.D. (UT Southwestern Medical Center)</i>
12:30 PM - 12:50 PM	Lessons from Academic Urology in Fostering Surgeon Leadership <i>Sam Chang, M.D., M.B.A (Vanderbilt University Medical Center)</i>
12:50 PM - 1:05 PM	Panel / Discussion
1:05 PM	ADJOURN

**Request for Taxpayer
Identification Number and Certification**

Go to www.irs.gov/FormW9 for instructions and the latest information.

**Give form to the
requester. Do not
send to the IRS.**

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type. See Specific Instructions on page 3.	1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.) Mayo Clinic	
	2 Business name/disregarded entity name, if different from above.	
	3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only one of the following seven boxes. ☐ Individual/sole proprietor ☐ C corporation ☐ S corporation ☐ Partnership ☐ Trust/estate ☐ LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) _____ Note: Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner. ☒ Other (see instructions) 501 (c) (3) Tax-exempt Nonprofit Corporation	4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3): Exempt payee code (if any) 1 Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any) A (Applies to accounts maintained outside the United States.)
	3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions ☐	
	5 Address (number, street, and apt. or suite no.). See instructions. 200 First Street SW 6 City, state, and ZIP code Rochester, MN 55905 7 List account number(s) here (optional)	Requester's name and address (optional)

Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

Note: If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Social security number									
			-				-		
or									
Employer identification number									
4	1	-	6	0	1	1	7	0	2

Part II Certification

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here	Signature of U.S. person <i>Katy Domaille</i>	Date <i>01/02/2025</i>
------------------	---	----------------------------------

General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

What's New

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they